Statins and liver enzyme testing: New FDA package labeling

November 2012
Endocrine Today;Nov2012, Vol. 10 Issue 11, p58
A blog about the significance of elevated liver enzymes in patients on statins and the decision of the U.S. Food and Drug Administration (FDA) to remove the requirements for routine periodic monitoring of liver enzymes in patients on statins.


Related Articles

  • statins.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2197 

    A definition of the term "statins," which refers to any of the drugs from the class known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, is presented.

  • Use of n-of-1 trials to determine statin tolerability.  // Reactions Weekly;Apr2014, Vol. 1495 Issue 1, p4 

    The article presents the findings of a recent study that confirmed the feasibility and potential value of n-of-1 trials in providing a reliable means of assessing whether such symptoms are in fact attributable to the statin.

  • Statin Therapy: Not Just for Cholesterol Anymore? Luks, Andrew M. // Critical Care Alert;Dec2009, Vol. 17 Issue 9, p69 

    This retrospective cohort study demonstrated that statin use was associated with a reduction in mortality in patients with severe sepsis (APACHE II > 24), but had no effect on mortality in those with less severe disease.

  • Noncholesterol-Lowering Effects of Statins. Pierre-Paul, Daphne; Gahtan, Vivian // Vascular & Endovascular Surgery;Sep/Oct2003, Vol. 37 Issue 5, p301 

    Statins, 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, inhibit the rate-limiting enzyme in cholesterol synthesis and lead to a significant reduction of plasma lipid concentrations. As a clear correlation exists between serum cholesterol and cardiovascular risk, statins...

  • Exploiting a Physiological Regulator to Improve the Efficacy and Safety of Statins. Gill, Saloni; Brown, Andrew J. // Cardiovascular Drugs & Therapy;Apr2011, Vol. 25 Issue 2, p183 

    A letter to the editor is presented about the use of a physiological regulator to enhance the safety and efficacy of statins.

  • When to take statins; Lovaza versus OTC fish oil supplements. DeDea, Larissa // JAAPA: Journal of the American Academy of Physician Assistants (;May2011, Vol. 24 Issue 5, p23 

    The article offers the author's insights on the proper administration of statins, and on the difference between Lovaza and over-the-counter (OTC) fish oil supplements. The author says that it is still unknown whether taking statins during evening to lower cholesterol can lead to better results...

  • CoQ10. Delany, Richard M. // Total Health;Jun/Jul2003, Vol. 25 Issue 3, p29 

    Discusses the health benefits of coenzyme Q10 (CoQ10). Factors that contribute to the decrease in CoQ10 in the body; List of diseases which are alleviated by CoQ10; Effect of the combined use of CoQ10 and statin.

  • Regulation and degradation of HMGCo-A reductase. Panda, T.; Devi, V. Amutha // Applied Microbiology & Biotechnology;Dec2004, Vol. 66 Issue 2, p143 

    The enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) controls the biosynthesis of cholesterol. Hypercholesterolemia and atherosclerosis are critical health risk factors. One way of controlling these risk factors is to manipulate regulation as well as degradation of HMGR. At...

  • Statins "safe" in standard doses.  // Reactions Weekly;6/16/2007, Issue 1156, p5 

    The article discusses research being done on the safety of statins in clinical practice. It references a study by Jane Armitage published in the June 7, 2007 online issue of "Lancet" journal. It mentions that the proven impact of statins on risk of cardiovascular disease has been the driving...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics